HUTCHISON CHINA/S (NASDAQ:HCM)’s share price traded up 2.1% on Tuesday . The company traded as high as $18.25 and last traded at $18.59, 2,044 shares traded hands during mid-day trading. A decline of 99% from the average session volume of 136,892 shares. The stock had previously closed at $18.20.
A number of research firms have recently commented on HCM. BidaskClub downgraded shares of HUTCHISON CHINA/S from a “buy” rating to a “hold” rating in a report on Saturday. Zacks Investment Research downgraded shares of HUTCHISON CHINA/S from a “buy” rating to a “hold” rating in a report on Friday. ValuEngine raised shares of HUTCHISON CHINA/S from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Macquarie began coverage on shares of HUTCHISON CHINA/S in a report on Friday, July 5th. They set an “outperform” rating for the company. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $25.41.
The business’s fifty day moving average price is $19.80 and its 200 day moving average price is $24.19. The company has a market capitalization of $2.40 billion, a P/E ratio of -33.18 and a beta of 0.64. The company has a current ratio of 2.80, a quick ratio of 2.67 and a debt-to-equity ratio of 0.01.
About HUTCHISON CHINA/S (NASDAQ:HCM)
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.
Read More: How does new data get added to a blockchain?
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.